Evidence map›Paper›PMID 36428813›Full record

ArticleCancers2022

Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma.

Jiazhou Ye, Yan Lin, Xing Gao, Lu Lu, Xi Huang, Shilin Huang, Tao Bai, Guobin Wu, Xiaoling Luo, Yongqiang Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jiazhou YeDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yan LinDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID 0000-0001-8034-5946
Xing GaoDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Lu LuDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xi HuangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Shilin HuangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Tao BaiDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Guobin WuDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xiaoling LuoDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yongqiang LiDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Rong LiangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Guangxi Medical University · CN

Funding

Advanced Innovation Teams and Xinghu Scholars Program of Guangxi Medical University 2021007Guangxi Key Research and Development Plan GUIKEAB19245002Guangxi Medical University Training Program for Distinguished Young Scholars 2020038Guangxi Natural Science Foundation NO. 2020GXNSFAA259080Guangxi Scholarship Fund of Guangxi Education Department 2020037Nanning 2021012National Natural Science Foundation of China 82060427National Natural Science Foundation of China 82103297Science and Technology Plan Project of Qingxiu District 2021010
6 · The paper itself

Abstract

Bioinformatics tools were used to identify prognosis-related molecular subtypes and biomarkers of hepatocellular carcinoma (HCC). Differential expression analysis of four datasets identified 3330 overlapping differentially expressed genes (DEGs) in the same direction in all four datasets. Those genes were involved in the cell cycle, FOXO signaling pathway, as well as complement and coagulation cascades. Based on non-negative matrix decomposition, two molecular subtypes of HCC with different prognoses were identified, with subtype C2 showing better overall survival than subtype C1. Cox regression and Kaplan-Meier analysis showed that 217 of the overlapping DEGs were closely associated with HCC prognosis. The subset of those genes showing an area under the curve >0.80 was used to construct random survival forest and least absolute shrinkage and selection operator models, which identified seven feature genes (SORBS2, DHRS1, SLC16A2, RCL1, IGFALS, GNA14, and FANCI) that may be involved in HCC occurrence and prognosis. Based on the feature genes, risk score and recurrence models were constructed, while a univariate Cox model identified FANCI as a key gene involved mainly in the cell cycle, DNA replication, and mismatch repair. Further analysis showed that FANCI had two mutation sites and that its gene may undergo methylation. Single-sample gene set enrichment analysis showed that Th2 and T helper cells are significantly upregulated in HCC patients compared to controls. Our results identify FANCI as a potential prognostic biomarker for HCC.

Indexed as

bioinformaticsFANCIhepatocellular carcinomamolecular subtypesprognostic biomarker

Identifiers

PMID36428813
PMCPMC9688639
OpenAlexW4309711128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.